Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2024.1370411
Abstract: Myasthenia gravis (MG) is an antibody-mediated autoimmune disease with a prevalence of 150–250 cases per million individuals. Autoantibodies include long-lived antibodies against the acetylcholine receptor (AChR), mainly of the IgG1 subclass, and IgG4, produced almost… read more here.
Keywords: autoantibody; treatment; prospects novel; myasthenia gravis ... See more keywords